Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients

被引：61
|
作者：
Suzuki, A
Otani, K
Mihara, K
Yasui, N
Kaneko, S
Inoue, Y
Hayashi, K
机构：
[1] YAMAGATA UNIV,SCH MED,DEPT NEUROPSYCHIAT,YAMAGATA 99023,JAPAN
[2] YOSHITOMI PHARMACEUT IND LTD,CTR PHARMACEUT TECHNOL,FUKUOKA 871,JAPAN
[3] GUNMA UNIV,SCH HLTH SCI,DEPT ALLIED MED SCI,MAEBASHI,GUMMA 371,JAPAN
来源：
PHARMACOGENETICS | 1997年 / 7卷 / 05期
关键词：
CYP2D6; genotype; haloperidol; reduced haloperidol; steady-state plasma concentration;
D O I：
10.1097/00008571-199710000-00013
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：415 / 418
页数：4
相关论文
共 50 条
  • [1] Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
    Mihara, K
    Suzuki, A
    Kondo, T
    Yasui, N
    Furukori, H
    Nagashima, U
    Otani, K
    Kaneko, S
    Inoue, Y
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (03) : 291 - 294
  • [2] Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients
    Pan, LP
    Vander Stichele, R
    Rosseel, MT
    Berlo, JA
    De Schepper, N
    Belpaire, FM
    THERAPEUTIC DRUG MONITORING, 1999, 21 (05) : 489 - 497
  • [3] CYP2D6 genotype and plasma levels of haloperidol and reduced haloperidol in Japanese
    Kondo, T
    Suzuki, A
    Mihara, K
    Yasui, N
    Kaneko, S
    MOLECULAR MEDICINE: NOVEL FINDINGS OF GENE DIAGNOSIS, REGULATION OF GENE EXPRESSION, AND GENE THERAPY, 1999, 1172 : 81 - 86
  • [4] Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
    Roh, HK
    Chung, JY
    Oh, DY
    Park, CS
    Svensson, JO
    Dahl, ML
    Bertilsson, L
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (03) : 265 - 271
  • [5] Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients:: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism
    Yasui, N
    Kondo, T
    Otani, K
    Furukori, H
    Mihara, K
    Suzuki, A
    Kaneko, S
    Inoue, Y
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (02) : 149 - 154
  • [6] Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol
    Yasui-Furukori, N
    Kondo, T
    Suzuki, A
    Mihara, K
    Tokinaga, N
    Inoue, Y
    Otani, K
    Kaneko, S
    SCHIZOPHRENIA RESEARCH, 2001, 52 (1-2) : 139 - 142
  • [7] STEADY-STATE PHARMACOKINETICS OF HALOPERIDOL AND REDUCED HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS - ANALYSIS OF FACTORS DETERMINING THEIR CONCENTRATIONS IN HAIR
    UEMATSU, T
    MATSUNO, H
    SATO, H
    HIRAYAMA, H
    HASEGAWA, K
    NAKASHIMA, M
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (10) : 1008 - 1011
  • [8] Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
    Mihara, K
    Suzuki, A
    Kondo, T
    Yasui, N
    Furukori, H
    Nagashima, U
    Ono, S
    Kaneko, S
    Otani, K
    Inoue, Y
    THERAPEUTIC DRUG MONITORING, 2000, 22 (03) : 245 - 249
  • [9] Impact of CYP2D6 genotypes on the steady-state plasma concentrations of paroxetine in Japanese psychiatric patients
    Ueda, M
    Hirokane, G
    Morita, S
    Okawa, M
    Shimoda, K
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (03) : 178 - 178
  • [10] CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients
    Shimoda, K
    Morita, S
    Yokono, A
    Someya, T
    Hirokane, G
    Sunahara, N
    Takahashi, S
    THERAPEUTIC DRUG MONITORING, 2000, 22 (04) : 392 - 396
12345